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Synthetic antisense oligomers are DNA mimics that can specifically inhibit gene
expression at the translational level by ribosomal steric hindrance. They bind to their
mRNA targets by Watson-Crick base pairing and are resistant to degradation by both
nucleases and proteases. A 25-mer phosphorodiamidate morpholino oligomer (PMO)
and a 13-mer polyamide (peptide) nucleic acid (PNA) were designed to target mRNA
(positions −4 to +21, and –17 to –5, respectively) close to the translational initiation
site of the extended-spectrum β-lactamase resistance genes of CTX-M group 1. These
antisense oligonucleotides were found to inhibit β-lactamase activity by up to 96% in
a cell-free translation-transcription coupled system using an expression vector carrying
a blaCTX M 15 gene cloned from a clinical isolate. Despite evidence for up-regulation− −
of CTX-M gene expression, they were both found to significantly restore sensitivity to
cefotaxime (CTX) in E. coli AS19, an atypical cell wall permeable mutant, in a dose
dependant manner (0-40 nM). The PMO and PNA were covalently bound to the cell
penetrating peptide (CPP; (KFF)3K) and both significantly (P < 0.05) increased sensitivity
to CTX in a dose dependent manner (0-40 nM) in field and clinical isolates harboring
CTX-M group 1 β-lactamases. Antisense oligonucleotides targeted to the translational
initiation site and Shine-Dalgarno region of blaCTX−M−15 inhibited gene expression,
and when conjugated to a cell penetrating delivery vehicle, partially restored antibiotic
sensitivity to both field and clinical isolates.
Keywords: CTX-M, ESBL, translational inhibition, E. coli, antisense oligonucleotides, PMO, PNA
INTRODUCTION
As a consequence of the well documented and ever increasing prevalence of antibiotic resistant
bacteria, new methods of combating resistant strains which are pathogenic are urgently required
for both animal and human health.
Particularly widespread in most countries in the northern hemisphere are the strains
of Escherichia coli carrying group 1 blaCTX−M, conferring resistance to third generation
cephalosporin antibiotics. First described in 1986, the CTX-M β-lactamases, named for their high
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level of activity against cefotaxime (CTX), and first observed in
Munich (M), are a group of rapidly spreading ESBLs and are now
the dominant family, especially found in such bacteria as E. coli
and K. pneumoniae (Rossolini et al., 2008). They have spread
globally and are common in many countries including the UK
and USA (Canton et al., 2012). They appear to have a separate
evolutionary history from other β-lactamases such as TEM and
SHV and their ESBL-variants, with which they superficially share
similar activity (Bonnet, 2003).
A variety of synthetic antisense/anti-gene agents, including
phosphorodiamidate morpholino oligonucleotides (PMOs) and
polyamide (peptide) nucleic acids (PNAs) have proven successful
in inhibiting the expression of a diverse range of targeted
bacterial genes (Rasmussen et al., 2007), demonstrating their
potential to form the basis of novel antimicrobial therapeutic
alternatives to traditional antibiotics (Woodford and Wareham,
2009; Goh et al., 2014). Synthetic translational inhibition
agents have been shown to be effective in vitro, and in
bacterial mutant strains with atypically permeable membranes,
but have little activity in field isolates with intact cell
walls, which restrict cytosolic entry (Good et al., 2000).
However, when attached to a CPP, usually comprising of
basic amino acids, the uptake of antisense agents in to the
bacterial cell may be greatly increased (Shiraishi and Nielsen,
2011).
Phosphorodiamidate morpholino oligonucleotides are
synthetic DNA analogs, incorporating natural DNA bases with
a backbone consisting of a six membered morpholine ring
with phosphorodiamidate linkages (Summerton et al., 1997).
PNAs also comprised of natural DNA bases but a backbone
of repeated N-(2-aminoethyl) glycine units linked by peptide
bonds (Soomets et al., 1999). PNAs, with a lack of charge in the
polyamide backbone, do not suffer from electrostatic repulsion
associated with natural DNA-RNA (or combinations thereof)
interactions (Armitage, 2003), which facilitates membrane
transfer and yields a high DNA/RNA binding affinity. These
oligonucleotides are resistant to enzymatic degradation, have
a net neutral charge at physiological pH, and are able to block
protein translation at the ribosome by the steric hindrance of
complementary base pairing with mRNA (Lecosnier et al.,
2011). The most effective area for translational protein
expression inhibition in bacteria has been shown to be the
Shine-Dalgarno (SD) ribosome binding site and the start codon
region of the mRNA (Good and Nielsen, 1998; Dryselius et al.,
2003).
Restoration of antibiotic sensitivity through translational
inhibition of β-lactamase activity potentially might represent a
viable therapeutic solution with the flexibility to quickly develop
new inhibitory agents targeted to specific genes and perhaps
restore the efficacy of certain now obsolete antibiotics. This is a
potential alternative strategy at the translational molecular level
for the treatment of CTX resistant bacteria. Resistance would
be unlikely to evolve quickly in the highly conserved targeted
ribosomal binding/translational start region.
Unmodified synthetic antisense oligonucleotides are known to
be unable to efficiently penetrate the bacterial cell wall (Good
et al., 2000). At around 2–3 kDa a 10-mer oligonucleotide is
too large to enter a bacterial cell by porin-mediated passive
transport (Nekhotiaeva et al., 2004), and therefore a delivery
strategy to overcome this barrier is required. CPPs are short
peptides of amino acids usually less than 30 residues in length,
and usually consisting of a repeating pattern of positively
charged and hydrophobic neutral residues, which are able to
traverse a bacterial cell wall (Bechara and Sagan, 2013). A cargo
molecule can be attached, usually by a direct covalent bond, to
a CPP which is then translocated with the CPP across the cell
membrane into the cytoplasm (Shiraishi and Nielsen, 2011). This
approach has been shown to be effective in delivering synthetic
antisense cargo molecules in eukaryotic cell lines (Shiraishi
and Nielsen, 2011), and bacterial strains (Ghosal and Nielsen,
2012).
We have designed and developed two antisense oligo-
nucleotides, a 25-mer PMO (PMO1), and a 13-mer PNA (PNA4)
to target areas of blaCTX−M group 1 genes, inhibit β-lactamase
expression and restore antibiotic sensitivity. We show sequence
specific blaCTX−M group 1 expression inhibition by a peptide
conjugated PMO (P-PMO1) and a peptide conjugated PNA (P-
PNA4), and a resultant phenotypic increase in sensitivity to the
third generation cephalosporin antibiotic CTX in human clinical
and veterinary field isolates.
MATERIALS AND METHODS
Antisense Oligomers
PMO1 was synthesized by GeneTools, LLC (Philomath, OR,
USA), with the base sequence of: agggtaccaattttttagtgacgcg
(estimated purity > 92%). PNA4 was synthesized commercially
by either Cellmano Biotech (Hefei, China) (purity D 95.51%),
or Cambridge Research Biochemicals (Cleveland, UK) with
the base sequence of: ggttattccttct. Peptide conjugated PMO1
(P-PMO1) and peptide conjugated PNA4 (P-PNA4) were
synthesized commercially by Cambridge Research Biochemicals
(Cleveland, UK), with the amino acid sequence of the CPP of
KFFKFFKFFK.
Strains
Strains used in this study are shown in Table 1. E. coli
strains of human (clinical) origin were obtained from the
Public Health laboratory, UK. AS19 was donated by Liam
Good (RVC, London), BZ693/P, B3804 and LREC525 were
from the collection of field strains at the Animal and
Plant Health Agency. LREC90, used for control studies,
carried a plasmid harboring blaCTX−M−14, which encoded
β-lactamase from CTX-M-group 9. All other CTX resistant
strains used in this study harbored variants of CTX-M-
group 1.
Construction of blaCTX−M−15 Expression
Plasmid
Plasmid pJBRCTX516 was constructed carrying a single
copy of blaCTX−M−15 cloned from a field isolate harboring
plasmid pEK516 (Woodford et al., 2009). ISEcp1 harbors
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TABLE 1 | Details of strains used in this study.
Strain reference Plasmid blaCTX−M Source
Species
MIC–CTX
mg/L
MIC–CTX +
P-PMO1
(30 µM) mg/L
MIC–CTX +
P-PNA4 (3.2
µM) mg/L
AS19 (Sekiguchi and Iida, 1967) pJBRCTX516 CTX-M-15 Lab strain 80 4† 2∗
LREC460 pEK516 (Woodford
et al., 2009)
CTX-M-15 Human 100 32‡ 24
LREC454 pEK499 (Woodford
et al., 2009)
CTX-M-15 Human 110 24 2
BZ693/P (Randall et al., 2011) Not known CTX-M-3/33 Chicken 40 15 12
B3804 (Freire Martin et al., 2014) pIFM3804 CTX-M-1 Pig 48 10 2
LREC525 (Randall et al., 2011) Not known CTX-M-15 Turkey 260 96 48
LREC461 pEK204 (Woodford
et al., 2009)
CTX-M-3 Human 35 16 8•
LREC90 Not known CTX-M-14 Cattle 20 – 20
References show either plasmid or strain characteristics/sequences. †PMO, concentration of 40 µM; ∗PNA concentration of 20 µM; ‡P-PMO concentration of 40 µM;
•P-PNA concentration of 5 µM.
TABLE 2 | PCR primer pairs for the amplification of blaCTXM15 and
associated upstream region.
Designation DNA Sequence Amplicon Amplicon
(5′ to 3′) Size (bp)
CTXM-pEK516
Forward ACTCAagatctGAAATTCA
GCTTTCACCCATTG
CTX-M-15 and
IS26 from pEK516
2552
Reverse CCATGTcctaggCCGTTTC
CGCTATTACAAAC
CTXM-pEK499
Forward TACTGGcatatgCGCTTGT
GATTCGCCGCCGTCAGG
TTGA
CTX-M-15 and
ISEcp1from
pEK499
2119
Reverse GAGCGTggatccCCGTTTC
CGCTATTACAAAC
Restriction enzyme recognition sites are lower case bold.
at least one blaCTX−M−15 promoter (Poirel et al., 2003;
Dhanji et al., 2011; Kamruzzaman et al., 2015). To ensure all
native regulatory elements were included in the recombinant
plasmid and that a valid genetic environment was replicated
for an evaluation of the inhibitory potential of the antisense
oligonucleotides, blaCTX−M−15 and the associated upstream
insertional element ISEcp1 was amplified by PCR (primers
shown in Table 2, incorporating the restriction enzyme
recognition sites XbaI and BamHI). This amplicon was TA
cloned into cloning vector pCRTM2.1-TOPO (Invitrogen). It
was screened on LB agar supplemented with CTX (2 mg/L)
and cultured in liquid LB overnight. The recombinant
plasmid was digested with BamHI and XbaI and the cloned
insert isolated by gel purification. This was the ligated into
the multi-cloning site (MCS) of the commercially available
plasmid vector pET-9a (Novagen) and screened on LB agar
supplemented with kanamycin (40 mg/L) and CTX (2 mg/L).
The recombinant plasmid was designated pJBRCTX516.
The successful construction of this plasmid was verified
by restriction enzyme digestion and gel electrophoresis,
and then by sequencing. An A to G point mutation at
position +823 was corrected by site-directed mutagenesis
using the GENEARTr Site-Directed Mutagenesis System
(Invitrogen).
Quantification of β-Lactamase CTX-M
Activity
CTX-M enzyme activity was determined by measuring the
degradation of CTX with an HPLC based assay. Overnight
cultures of strains were prepared and grown in Mueller-
Hinton Broth (MHB) to O.D.600 nm 0.6-0.8 (mid-log phase),
with antibiotic supplements where required. Cell aggregates
were disrupted by bead milling in a Retsch Mixer MM301
shaking homogeniser (F. Kurt Retsch GmbH, Haan, Germany)
at full speed for 5 min with 0.2-0.4 mm glass beads.
The cells were collected by centrifugation at 10,000g for
2 min and the supernatant retained. A suitable volume
of supernatant was incubated at 37◦ C with the desired
concentration of CTX solution for varying amounts of time.
Enzymatic activity was halted by transferring incubation
solution (125 µl) to pre-prepared HPLC vials containing
125 µl phosphate buffer (pH2.2). The HPLC method used
was adapted from Nemutlu et al. (2009) for the detection of
CTX and other cephalosporins. HPLC was performed using a
Xterra C18 (250 mm × 4.6 mm, 5 µm, i.d.) column using
Agilent Technologies 1100 series liquid chromatography system
comprising of automated solvent delivery, sampler and array
detector system. The following chromatographic conditions were
used. Phosphate buffer (sodium dihydrogen orthophosphate
dihydrate 40 mM; pH3.2) was mixed with 100% MeOH during
automated analysis with a gradient pump to the following
amounts (MeOH: Phosphate buffer); t = 0 mins 18:82%,
t = 5 mins 18:82%; t = 15 mins 45:55%; t = 16 mins 55:45%;
t = 21 mins 55:45%; t = 22 mins 18: 82%; t = 30 next injection
at a flow rate of 0.85 ml/min, with an injection volume of 25 µl
per sample. CTX was detected in HPLC eﬄuent at a wavelength
of 254 nm. Analysis was performed with ChemStation software
(Agilent Technologies). CTX was quantified using a standard
calibration curve (0-400 mg/L CTX). The activity of blaCTX−M
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was expressed as CTX (µg) degraded per minute per bacterial
cell.
Inhibition of blaCTX−M−15 Activity by
Synthetic Antisense Oligonucleotides in
a Cell-Free Translation/Transcription
Coupled System
The ExpresswayTM Mini Cell-Free Expression System
(InvitrogenTM) was used for all in vitro protein expression
studies. The manufacturer’s supplied protocol was followed and
the reaction mixture was incubated with plasmid pJBRCTX516
(1 ng), purified by peqGOLD Plasmid Miniprep Kit (Peqlabr
Ltd) and amount estimated by spectrophotometry. β-Lactamase
activity was determined by HPLC as described above.
Cell Growth Assay for Assessing the
Activity of Antisense Oligonucleotides
The activity of antisense oligonucleotides was assessed by
measuring their ability to restore the growth inhibitory effect
of CTX in a cell growth assay. Bacterial cultures were typically
grown from glycerol stocks at 37◦C in a shaking incubator in
MHB media containing CTX (2 mg/L) until early log phase
(0.1–0.2 O.D.600 nm) was achieved. The culture was diluted to
achieve a final cell density of approximately 100,000 CFU/ml,
previously established empirically to be optimal for assessing the
effect of antisense oligonucleotides, and for consistency across
experiments. Diluted cell suspension (50 µl) was incubated with
MHB (50 µl) growth medium supplemented with antibiotics
and inhibitory agents where required, and transferred to a 96
well microtiter plate (Falcon). CTX concentrations for blaCTX−M
inhibition studies were set at a level required to increase the
dormant lag phase by 1-3 h, as established in the current study
(not shown). This was determined to be an optimal concentration
to yield observable effects of synergistic antisense-CTX activity
and was strain dependent. Bacterial cell growth was measured in
a BMG Labtech FluoStar automated spectrophotometer (BMG
LABTECH GmbH, Ortenberg, Germany) and optical density
readings (600 nm filter) taken over 18-24 h. The O.D.600 nm
filter readings were taken over 250 cycles, with 15 flashes
per well per cycle approximately every 5 min. All replicates
were independent cultures. Growth curves and statistical
analyses were produced using Prismr 6 software (GraphPad).
Minimum inhibitory concentrations (MICs) were determined
to be the minimum antibiotic concentration observed by
spectrophotometry required to completely inhibit growth in
≥50% of replicates over 18 h in the cell growth assay.
Experimental Controls Used for the
Evaluation of Inhibition of β-Lactamase
Activity by Unmodified and
Peptide-Conjugated PNA4/PMO1
Specificity and any inherent toxicity of peptide-conjugated
and unmodified PNA4 and PMO1 were demonstrated in
the following studies. A scrambled non-specific 25-mer PMO
was incubated in the presence of pJBRCTX516 in a cell-
free translation/transcription coupled system followed by the
quantification of cefotaximase activity. AS19/pJBRCTX516 was
cultured with the scrambled PMO in the presence and absence
of CTX and growth measured by spectrophotometry over 18–
24 h. Field isolates harboring blaCTX−M−group1 were cultured
in the presence of P-PMO1 or P-PNA4 in the absence of CTX
and growth measured by spectrophotometry over 18–24 h. The
targeting of the non-essential blaCTX−M gene allowed the use of
P-PMO1 and P-PNA4 in the absence of CTX as a highly suitable
control for isolating the effects of the antisense agents and/or
CPP on growth. Controls in the absence of CTX were included
with every study. Field isolate LREC90 harboring blaCTX−M−14
(non-complementary with anti-blaCTX−M−15 PNA4 and PMO1;
Figure 1B) was cultured in the presence and absence of P-PNA4,
P-PMO1, and CTX, and growth measured by spectrophotometry
over 18–24 h. Minimum inhibitory concentrations (CTX) were
established for LREC90 in the presence and absence of P-PNA4.
RESULTS
Design of Antisense Oligonucleotides
Targeting the Translation Initiation
Region of blaCTX−M−15 mRNA
A 25 base PMO (PMO1) oligonucleotide was designed to target,
by complementary base pairing, an area covering both the SD
region and translational start codon region of blaCTX−M−15
mRNA (Figure 1A). However, due to potential hairpin self-
dimerization and homo-dimerization, the design was modified
under the advice of the manufacturer (Gene Tools LLC) and the
final design was complementary to mRNA positions -4 to +21,
with a sequence of: agggtaccaattttttagtgacgcg (Figure 1A). The
target sequence was checked by NCBIs Basic Local Alignment
Search Tool (BLAST) for homology with other bacterial and
mammalian genes for potential unwanted off-target effects. This
sequence was found by BLAST to be 100% complementary with
all group 1 CTX-M β-lactamases. No bacterial off-target matches
were found with greater than 72% sequence identity and no
mammalian gene transcripts were found with a greater than 72%
sequence identity.
A 13 base PNA (PNA4) was designed to target the SD
region of blaCTX−M−15 mRNA (Figure 1A) with 100% sequence
complementarity to the extragenic region -17 to -5. This target
sequence was checked by BLAST and found to be to be 100%
complementary with all group 1 CTX-M β-lactamases. Four
bacterial off-target matches were found with 92.3% sequence
similarity (12 out of 13 bases). A large number (>50) of off-target
mammalian transcripts were detected (13 out of 13 bases).
Construction of a Prokaryotic Expression
Plasmid Harboring the blaCTX−M−15 Gene
Plasmid pJBRCTX516 was extracted and the successful
recombination verified by restriction enzyme digestion and
by sequencing (not shown). The plasmid vector contained T7
promoter and terminator regions flanking the MCS, making
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FIGURE 1 | (A) Alignment of blaCTX−M−15 with PMO1 and PNA4. PMO1 was designed to target, by complementary base-pairing, to blaCTX−M−15 mRNA from
positions −4 to +21. PNA4 was designed to target blaCTX−M−15 mRNA from positions −5 to +17. The Shine-Dalgarno region (SD) is marked in bold uppercase
and the translational start codon region is bold uppercase and underscored. ∗represent complementary bases. (B) Lack of alignment from the start codon of
blaCTX−M−14 with PMO1 and PNA4. blaCTX−M−14 is a mismatched control for anti-blaCTX−M−15 PNA4 and PMO1. Best alignment of PMO1 = 56%
complementarity. Best alignment of PNA4 = 15% complementarity. ∗represent complementary bases.
FIGURE 2 | β-Lactamase CTX-M-15 and its associated upstream
insertional element ISEcp1 were cloned into the commercially
available vector pET-9a to create an expression vector which, by virtue
of the T7 promoter and termination sequences, could also be used in
an in vitro cell-free transcription-translation coupled system. This
plasmid harbored no native β-lactamase genes, and kanamycin resistance for
selection purposes.
it a suitable vector for both cell-free and whole-cell inhibition
experimental studies (Figure 2).
Expression of blaCTX−M−15 in a Cell-Free
Transcription/Translation System is
Inhibited by Antisense Oligonucleotides
PMO1 significantly (P < 0.05) inhibited β-lactamase in a
dose dependent manner (50-1000 nM). The following rates of
CTX degradation were observed: uninhibited control sample:
1.01 µg/min/ng plasmid, 50 nM PMO: 0.34 µg/min/ng plasmid
(66.05% inhibition), 100 nM PMO: 0.27 µg/min/ng plasmid
(73% inhibition), 250 nM PMO: 0.15 µg/min/ng plasmid
(85.33% inhibition), 500 nM PMO: 0.08µg/min/ng plasmid (92%
inhibition) and 1000 nM PMO: 0.04 µg/min/ng plasmid (96.08%
inhibition). A non-complementary scrambled control PMO had
no inhibitory effects on β-lactamase activity (not shown). PNA4,
under the same conditions showed a similar, dose dependent
effect ranging from 50% inhibition of CTX degradation at 50 nM
PNA4, to 90% inhibition at 1000 nM PNA4.
Levels of blaCTX−M Activity in a
Laboratory Cell-Wall Mutant Strain of
E. coli are Reduced by Antisense
Oligonucleotide Treatment
An increased sensitivity to CTX (4 mg/L) was shown in a dose
dependant manner (20-40 µM PMO1 and 5-30 µM PNA4), with
growth completely inhibited at PMO1 concentration of 40 µM
(Figure 3). When treated with CTX (2 mg/L), 20 µM PNA4 was
sufficient to completely inhibit growth (not shown).
There was no observed increase in CTX sensitivity when
atypically permeable strain AS19/pJBRCTX516 was challenged
with the combination of non-blaCTX−M specific control PMO
and CTX. In the absence of CTX, no effects on growth were
observed when AS19/pJBRCTX516 was challenged with PMO1
alone (10–30 µM, Figure 3). In the absence of CTX, significant
effects on growth were observed when AS19/pJBRCTX516 was
challenged with PNA4 alone at concentrations higher than
5 µM (Figure 3). This was potentially attributable to unintended
off-target partial complementarity with other bacterial genes.
Consequently, PNA4 concentrations in subsequent studies did
not exceed a concentration of 5 µM.
Levels of blaCTX−M Activity in Field and
Clinical Isolate Strains of E. coli are
Effectively Reduced by Treatment with
Antisense Oligonucleotides Conjugated
to a CPP
Field isolate LREC460 harboring the resistance plasmid pEK516
and field isolate LREC461 harboring the resistance plasmid
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FIGURE 3 | Effects of unmodified anti-blaCTX−M−15 PMO1 and PNA4 alone, and in the presence of CTX on AS19/pJBRCTX516 growth. E. coli strain
AS19 harboring plasmid pJBRCTX516 was incubated in the presence and absence of PMO1, PNA4, and CTX with culture growth measured at 600 nm over
18–22 h. (A) Solid line: control, dashed lined: PMO1 (5 µM), dotted line: PMO1 (10 µM), dash–dot line: PMO1 (20 µM), dash–dot–dot line: PMO1 (30 µM). (B) Solid
line: CTX (4 mg/L), dashed lined: CTX (4 mg/L) + PMO1 (10 µM), dotted line: CTX (4 mg/L) + PMO1 (20 µM), dash–dot line: CTX (4 mg/L) + PMO1 (30 µM),
dash–dot–dot line (no growth): CTX (4 mg/L) + PMO1 (40 µM). (C) Solid line: control, dashed lined: PNA4 (5 µM), dotted line: PNA4 (10 µM), dash-dot line: PNA4
(20 µM), dash–dot–dot line: PNA4 (30 µM). (D) Solid line: CTX (4 mg/L), dashed lined: CTX (4 mg/L) + PNA4 (10 µM), dotted line: CTX (4 mg/L) + PNA4 (20 µM).
Error bars illustrated in gray indicate ±1 SD (n = 2).
pEK204, were incubated in Mueller Hinton Broth and challenged
with CTX (16–32 mg/L) and PMO1/PNA4 (5–40 µM). It
was found that neither PMO1 nor PNA4 had observable
effects on growth or cell viability (data not shown). This
was consistent with prior expectations as the cell wall has
been previously shown to be a significant barrier to gene
expression inhibition by antisense/antigene chemistries (Good
et al., 2000).
A panel of clinical and field E. coli isolates were selected
and MICs to CTX established (Table 1). These strains were
challenged with a range of P-PMO1 and P-PNA4 concentrations
in combination with the concentration of CTX required to extend
the lag phase by 1-3 h (Table 1).
P-PMO1 was tested in combination with CTX in a
range of six field and clinical isolates harboring plasmids
carrying different group 1 CTX-M genes. All isolates tested
showed an increased sensitivity to CTX when treated with
anti-blaCTX−M P-PMO1 (30 µM) ranging from a reduction
in the MIC (to CTX) in blaCTX−M−3-harboring strain from
35 to 16 mg/L (2.19-fold increase in sensitivity), to a strain
harboring blaCTX−M−1 from 48 to 10 mg/L (4.8-fold increase
in sensitivity). The same isolates when treated with P-PNA4
(3.2 µM) had an observed increase in CTX sensitivity ranging
from a reduction in MIC (to CTX) in blaCTX−M−3/33-harboring
strain BZ693/P from 40 to 12 mg/L (3.3-fold) to a strain
harboring blaCTX−M−15 (LREC454) from 110 to 2 mg/L (55-
fold).
Any potential effects on bacterial culture growth not
attributable to inhibition of blaCTX−M−15 were isolated by
the treatment of cultures with P-PNA4 or P-PMO1 in the
absence of CTX. In all strains tested, including strain LREC90
harboring blaCTX−M−14, both P-PMO1 and P-PNA4 in the
absence of CTX individually had a small significant negative
effect on growth, characterized by an extended lag phase
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FIGURE 4 | Effects of P-PNA4 in the presence and absence of CTX on field isolate E. coli strain LREC90 (harboring blaCTX−M−14) and LREC454
(harboring blaCTX−M−15). blaCTX−M−14 was a mismatched control for P-PNA4. Strains were incubated in the presence and absence of P-PNA4 and CTX with
culture growth measured at 600 nm over 18 hours. (A) Field isolate LREC90 growth in the presence of increasing concentrations of CTX, lines from left to right:
control, CTX (0 mg/L), CTX (2 mg/L), CTX (5 mg/L), CTX (8 mg/L), CTX (11 mg/L), CTX (14 mg/L), CTX (17 mg/L), CTX (20 mg/L). (B) Field isolate LREC90 in the
presence of P-PNA4 (3.2 µM) and increasing concentrations of CTX, lines from left to right: P-PNA4 (3.2 µM), CTX (0 mg/L) + P-PNA4 (3.2 µM), CTX (2 mg/L) +
P-PNA4 (3.2 µM), CTX (5 mg/L) + P-PNA4 (3.2 µM), CTX (8 mg/L) + P-PNA4 (3.2 µM), CTX (11 mg/L) + P-PNA4 (3.2 µM), CTX (14 mg/L) + P-PNA4 (3.2 µM), CTX
(17 mg/L) + P-PNA4 (3.2 µM), CTX (20 mg/L) + P-PNA4 (3.2 µM). (C) Field isolate LREC90 in the presence of P-PNA4 (1.6–5 µM), solid line: control, dashed line:
P-PNA4 (1.6 µM), dotted line: P-PNA4 (3.2 µM), dash–dot line: P-PNA4 (5 µM). (D) Field isolate LREC90 in the presence of CTX (2 mg/L) and P-PNA4 (1.6–5 µM),
solid line: CTX (2 mg/L), dashed line: CTX (2 mg/L) + P-PNA4 (1.6 µM), dotted line: CTX (2 mg/L) + P-PNA4 (3.2 µM), dash–dot line: CTX (2 mg/L) + P-PNA4
(5 µM). (E) Field isolate LREC454 in the presence of P-PNA4 (1.6–5 µM), solid line: control, dashed line: P-PNA4 (1.6 µM), dotted line: P-PNA4 (3.2 µM), dash–dot
line: P-PNA4 (5 µM). (F) Field isolate LREC454 in the presence of CTX (2 mg/L) and P-PNA4 (1.6–5 µM), solid line: CTX (2 mg/L), dashed line: CTX (2 mg/L) +
P-PNA4 (1.6 µM), dotted line: CTX (2 mg/L) + P-PNA4 (3.2 µM), dash–dot line: CTX (2 mg/L) + P-PNA4 (5 µM). Error bars illustrated in gray indicate ±1 SD (n = 2).
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FIGURE 5 | Effects of P-PMO1 in the presence and absence of CTX on field isolate E. coli strain LREC90 (harboring blaCTX−M−14) and LREC454
(harboring blaCTX−M−15). blaCTX−M−14 was a mismatched control for P-PMO1. Strains were incubated in the presence and absence of P-PMO1 and CTX with
culture growth measured at 600 nm over 18 h. (A) Field isolate LREC90 in the presence of P-PMO1 (10–30 µM), solid line: control, dashed line: P-PMO1 (10 µM),
dotted line: P-PMO1 (20 µM), dash–dot line: P-PMO1 (30 µM). (B) Field isolate LREC90 in the presence of CTX (3 mg/L) and P-PMO1 (10–30 µM), solid line: CTX
(3 mg/L), dashed line: CTX (3 mg/L) + P-PMO1 (10 µM), dotted line: CTX (3 mg/L) + P-PMO1 (30 µM). (C) Field isolate LREC454 in the presence of P-PMO1
(10–30 µM), solid line: control, dashed line: P-PMO1 (10 µM), dotted line: P-PMO1 (20 µM), dash–dot line: P-PMO1 (30 µM). (D) Field isolate LREC454 in the
presence of CTX (24 mg/L) and P-PMO1 (30 µM), solid line: control, dashed line: CTX (24 mg/L), dotted line: CTX (24 mg/L) + P-PMO1 (30 µM). Error bars
illustrated in gray indicate ±1 SD (n = 2).
period of variable, strain, and dose dependent amount. This
was attributed to the effect of the CPP, which has been
previously shown to have an impact on bacterial cell growth,
and a synergistic effect with some antibiotics (Mohamed et al.,
2014).
Evaluation of the Sequence Specificity of
Antisense Effects on Expression of
CTX-M-15 Activity in Field Isolates
Previous studies have shown limited or no effect of scrambled
or mismatch control peptide-conjugated PNAs on bacterial
growth, including mismatch controls containing as few as two
base substitutions (Ghosal and Nielsen, 2012). Studies with
the peptide (KFF)3K attached to PNAs have demonstrated the
efficacy of synthetic antigene oligonucleotides in bacteria, and
their specificity by demonstrating low inhibition of target and
reporter genes when challenged with scrambled non-specific
peptide-conjugated PNAs (Good et al., 2001).
Control studies, equivalent to the use of a scrambled non-
specific P-PNA or P-PMO1, were undertaken in E. coli strain
LREC90. PMO1 and PNA4 were non-specific to blaCTX−M−14
expressed by LREC90 (Table 1B). No significant differences
were observed between the effects on growth of LREC90
cultured in the presence of P-PNA4 alone (1.6–5 µM), and
P-PNA4 (1.6–5 µM) co-administered with CTX (2 mg/L).
Minimum inhibitory concentrations (CTX) of LREC90 were not
reduced in the presence of P-PNA4 (Figure 4). A comparable
effect on LREC90 (blaCTX−M−14) and LREC454 (blaCTX−M−15)
growth was observed when cultured in the presence of
P-PMO1 (10–30 µM), attributable to the peptide portion of the
conjugate.
The negative effect on growth was increased in an additive
manner (estimated fractional inhibitory concentration index
(FICI) between 0.5 and 1) when LREC90 was cultured in
the presence of P-PMO1 (10–30 µM) and CTX (3 mg/L), in
contrast, the negative effect was increased in a synergistic
manner (estimated FICI < 0.5) when LREC454 was
Frontiers in Microbiology | www.frontiersin.org 8 March 2016 | Volume 7 | Article 373
fmicb-07-00373 March 22, 2016 Time: 13:32 # 9
Readman et al. CTX-M Inhibition by Antisense Oligonucleotides
FIGURE 6 | Effect of exposure to the third generation cephalosporin
ceftriaxone (CRO) on the upregulation of cefotaximase activity in
recombinant E. coli strain AS19/pJBRCTX516. E. coli cultures of strain
AS19 harboring the plasmid pJBRCTX516, were incubated with
concentrations of CRO (2-64 mg/L) for 30 min. Supernatants were collected,
and incubated with CTX. A quantification of CTX degradation was established
by HPLC in aliquots collected at regular intervals over 50 min. CRO
concentrations were: zero (♦), 2 mg/L (4), 32 mg/L (©), and 64 mg/L ().
Filled triangles (N) represent HPLC negative control blank sample. Error bars
indicate ±1 SD (n = 2).
cultured in the presence of P-PMO1 and CTX (24 mg/L)
(Figure 5).
Cephalosporin Treatment Induces
Increased Levels of blaCTX−M−15 Activity
in E. coli Strains
The effect of exposure to an extended spectrum β-lactam on
the activity of CTX-M-15 activity was investigated by pre-
exposure to ceftriaxone (CRO; 2–384 mg/L) and subsequent
quantification of CTX degradation. The rate of CTX degradation
was increased in a dose dependent manner (2-64 mg/L)
following exposure to higher levels of ceftriaxone in both
AS19/pJBRCTX516 (Figure 6) and field isolate LREC460 (data
not shown).
DISCUSSION
The application of antisense oligonucleotides for the translational
inhibition of specific genes, such as those that confer resistance
to ESBLs, is an attractive potential strategy for the restoration of
antimicrobial sensitivity. PMOs and PNAs have been previously
successfully employed to inhibit bacterial protein expression
in a targeted, sequence specific manner. A wide range of
bacterial essential and non-essential gene transcripts have been
targeted and inhibited by synthetic antisense oligonucleotides.
For example, a 17-mer PNA was reported by Lecosnier et al.
(2011) to inhibit anti-insulin-like growth factor 1 receptor (IGF-
1R) by 70–80% (Lecosnier et al., 2011). Geller et al. (2005)
found that a 11-mer PMO significantly inhibited the viability
E. coli through targeted inhibition of an essential gene (acpP) for
phospholipid biosynthesis.
In this study, we have designed and evaluated a 25-mer
PMO (PMO1) and a 13-mer PNA (PNA4) antisense/antigene
oligonucleotide for efficacy of inhibition of translation of
blaCTX−M against a range of CTX-M group 1 β-lactamases
in E. coli. This was demonstrated in a sequential series of
progressive studies. β-lactamase was expressed in a cell free
transcription/translation assay using a recombinant plasmid
(pJBRCTX516) with a high amplitude promoter harboring
blaCTX−M−15 as template DNA in the presence and absence of
antisense oligonucleotides. β-lactamase activity was quantified
by subsequent incubation with CTX, and degradation was
quantified by an HPLC assay developed for the detection of
CTX.
Increases in sensitivity to CTX in E. coli strains with reduced
susceptibility to CTX (Table 1) were ascertained by cell growth
assays in the presence of CTX and antisense oligonucleotides.
In cell free studies, PMO1 was found to inhibit production
of blaCTX−M−15 in a dose-dependent (50-1000 nM) manner.
At 1000 nM, β-lactamase production was inhibited by 96.08%.
A scrambled control PMO of the same size, 25 nucleotides, non-
specific to any bacterial gene, was found to have no inhibitory
effects on transcription/ translation at this genetic level. These
data suggest a high sequence specific inhibitory potential of
PMO1 against blaCTX−M−group 1. Under the same conditions,
PNA4 was found to inhibit production of blaCTX−M−15 in a dose-
dependent (50–1000 nM) manner with a maximum inhibition at
1000 nM of 89.39%.
PMO1 was tested against the atypically permeable cell-
wall mutant AS19, transformed with pJBRCTX516 harboring
blaCTX−M−15. Specificity was demonstrated at the phenotypic
level as a scrambled control PMO with no specificity to bacterial
genes had no observable effects on cell growth. There were also no
observable effects when AS19/pJBRCTX516 was incubated with
the maximum concentration used in inhibition studies (40 µM)
PMO1 in the absence of CTX. There was a small observable lag
phase extension effect, in a dose dependent manner (2.5-20 µM),
when AS19/pJBRCTX516 was incubated with PNA4. This was
attributed to the off-target matches associated with the sequence
design of PNA4.
When incubated in the presence of both CTX and PMO1,
increased antibiotic sensitivity was observed in a dose-dependent
manner (10-40 nM). The MIC of CTX for this transformant,
AS19/pJBRCTX516, was 80 mg/L, in the presence of 40 µM
PMO1, this was reduced to 4 mg/L. These data demonstrated the
lack of any inherent toxicity of PMO1 at the concentrations used,
and the specific activity of PMO1 against blaCTX−M−15. Under
the same conditions, incubated in growth medium additionally
supplemented with PNA4 (20 µM), the minimum inhibitory
concentration was reduced to 2 mg/L. At 20 µM, PNA4 alone was
insufficient to inhibit growth and had a synergistic relationship
with CTX (FICI< 0.5).
When tested with E. coli field isolates LREC460 and LREC461
containing plasmids harboring CTX-M group 1 genes, neither
PMO1 nor PNA4 was found to have any effect on their
sensitivity to CTX, or to their growth characteristics. This was
Frontiers in Microbiology | www.frontiersin.org 9 March 2016 | Volume 7 | Article 373
fmicb-07-00373 March 22, 2016 Time: 13:32 # 10
Readman et al. CTX-M Inhibition by Antisense Oligonucleotides
not unexpected as previous studies have shown that E. coli
with an intact cell wall do not efficiently take up naked
antisense oligonucleotides (Good et al., 2000). To overcome
this barrier, the anti-blaCTX−M oligonucleotides PMO1 and
PNA4 were covalently bound to the CPP, (KFF)3K, which
has been shown to be effective in promoting uptake across
the bacterial cell wall and delivering a cargo molecule to the
cytoplasm (Good et al., 2001; Shiraishi and Nielsen, 2011).
In the presence of peptide-conjugated PMO1 and PNA4, an
increase in sensitivity to CTX was observed in all field isolates
tested.
The disparity in the efficacy of P-PNA4 compared with
P-PMO1 can, in part, be explained by the contribution of
the off-target effects of the shorter PNA. Four bacterial
gene transcripts shared 92.3% sequence identity with the
blaCTX−M target sequence (12 out of 13 bases), and an effect
on growth was shown when challenging AS19/pJBRCTX516
with PNA4 alone. The off-target effects, however, were small
in comparison with the synergistic effects of PNA4 in
combination with CTX, and although significant (P < 0.05),
were negligible at 3.2 µM. In the panel of six field and
clinical isolates, P-PNA4 was found to be between 9- and
56-fold more effective in increasing sensitivity to CTX than
P-PMO1.
When challenging the panel of strains with both P-PMO1
and P-PNA4 in the absence of CTX, a negative effect on
bacterial cell growth was observed. This effect, not observed
with unmodified oligonucleotides, can be attributed to the
CPP portion of the conjugate. This effect has been noted
by Bahnsen et al. (2013) and Mohamed et al. (2014) who
also noted a strong synergistic effect of (KFF)3K with
the antibiotics gentamicin and amikacin. It is likely that
at low concentrations, the mechanism of cell penetration
of (KFF)3K compromises the cell wall and increases the
uptake of antibiotics, as has been observed in other
bacterial species (Mohamed et al., 2014). Control studies
using P-PMO1 and P-PNA4 in the presence and absence
of CTX in strain LREC90 harboring blaCTX−M−14, to
which anti-blaCTX−M−15 P-PMO1 and P-PNA4 had only
partial sequence complementarity, revealed no synergistic
relationship with CTX. In addition, when strains harboring
blaCTX−M−15 were challenged with P-PMO1 and P-PNA4
alone, a comparable effect size to that shown in LREC90
was observed. Previously sub-lethal concentrations of CTX
were sufficient to completely inhibit growth of these group
1 strains when in the presence of P-PMO1 or P-PNA4 at
concentrations observed to have small or insignificant effects
alone.
Specificity and the effect on growth of the CPP were
demonstrated at the phenotypic level by the exposure of
E. coli strain LREC90, harboring blaCTX−M−14 to CTX alone
and in combination with P-PMO1 and P-PNA4. CTX-M-
14, a group 9 CTX-M enzyme, shared 15.4% sequence
complementarity (2 out of 13 bases) of the region targeted
by P-PNA4, and 56% sequence complementarity (14 out
of 25 bases) of the region targeted by P-PMO1. As such,
this was regarded as a comparable control to scrambled
non-specific antisense oligonucleotides in strains harboring
blaCTX−M−15.
A small effect on growth in the absence of CTX was observed,
attributable to the CPP portion of the conjugate, potentially a
result of membrane perturbation.
The relatively modest increase in sensitivity to CTX of
field isolates when co-administered with P-PMO1, contrasted
with a much higher level of re-sensitisation in the cell wall
compromised strain AS19 transformed with pJBRCTX516, and
a near complete inhibition of protein expression when tested in a
cell-free environment. This disparity suggested either inefficient
uptake of the antisense agent, a higher level of eﬄux in field
isolates, or greater β-lactamase expression in response to CTX
challenge.
We found experimental evidence to suggest that in conditions
of increasing concentrations of CTX, in both field isolates
and AS19/pJBRCTX516 there was a proportional up-regulation
of β-lactamase activity. The differential expression mechanism
requires further study.
The data obtained from translational inhibition studies
of blaCTX−M in field isolates, and the potential for
further optimisation and enhancement, demonstrated the
potential for therapeutic use of P-PMOs and P-PNAs in
re-sensitizing resistant bacteria to CTX. To our knowledge
this is the first study using synthetic oligonucleotides to
demonstrate inhibition of blaCTX−M group 1 genes in field
and clinical isolates and restore sensitivity to the third
generation cephalosporin CTX. Further studies are required
to optimize uptake into the bacterial cell and translational
inhibition.
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